Week 384 Review - Santa nowhere in sight as we plunge to a new all-time low

Yet another bad week in a month when we're supposed to get a rally. It was generally pretty flat, but a 0.75p fall in OPTI:Optibiotix made a big dent, as did the announcement of a placing by SBTX:SkinBioTherapeutics, with the deficit between cost and value widening by £1,818 to £117,087 and portfolio value dropping to £65,304. 

Worst performer on paper was my new purchase of III:3i Group as part of my monthly savings, but I only bought 9 shares so even a tiny buying commission of £1.50, when added to the selling commission of £9.95, means the £123 purchase was over 10% down as soon as I bought it. That will rectify as I add more over the next 10 months and the commission has less of an impact.

SBTX:SkinBioTherapeutics dropped 5% after announcement of a placing, so it's now pretty much at the placing price. I have subscribed for 2,500 shares as part of the retail offer, as there is no commission and I had a bit of spare cash in the accounts, plus I added a small amount because my car cost less to fix than I had budgeted for.

Share of the Week is the only big riser, with BLU:Blue Star Capital climbing 5% for no obvious reason. Still no sign of Satoshipay taking off, so not holding out much hope for these.

Even lower than last week

And what a surprise, we're back on the trend line and following it down

Here's the ISA and shares portfolio after week 20 of year 8.

			Weekly Change
Cash	£175.20		+£122.52
Portfolio cost	£82,003.25		+£0
Portfolio sell value (bid price-commission)	£25,365.66	(-69.1%)	-£817.14
Potential profits	£0		+£0
Yr 8 Dividends	£0		+£0
Yr 8 Interest	£0.05		+£0.02
Yr 8 Profit from sales	-£995.63		+£0
Yr 8 projected avg monthly profit	-£218.96	(-5.9%)	+£10.67
Total Dividends	£11,768.92		+£0
Total Interest	£0.05		+£0.02
Total Profit from sales	£27,098.43		+£0
Average monthly cash profit	£434.75	(11.7%)	-£1.18
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	87%		+0%

I added £130 to cover the SBTX:SkinBioTherapeutics subscription, and monthly fees were taken, and much excitement with 2p interest earned. Portfolio value dropped £817 which is normal in these dark times.

Desperate

Following the trend line down

The SIPP looks like this after week 368 overall and week 4 of year 8.

			Weekly Change
Cash	£639.11		+£93.65
Portfolio cost	£98,539.81		+£123.34
Portfolio sell value (bid price - commission)	£39,348.31	(-60.1%)	-£982.47
Potential profits	£229.89		-£29.78
Yr 8 Dividends	£0		+£0
Yr 8 Interest	£0.01		+£0.01
Yr 8 Profit from sales	£94.41		+£0
Yr 8 projected avg monthly profit	£88.19	(1.8%)	-£48.18
Total Dividends	£14,142.78		+£0
Total Interest	£0.26		+£0.01
Total Profit from sales	£20,528.16		+£0
Average monthly cash profit	£396.38	(8.0%)	-£1.23
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	57%		+0%

I added £100 towards the SBTX:SkinBioTherapeutics subscription, and portfolio cost went up £123 when I bought 9 share in III:3i Group at 1347.001p costing £123,34. Unfortunately they have already dropped to 1281.5p. I'll keep the monthly savings going for 10 months though, as I'll be buying cheaper each month if the price drops.

Portfolio value dropped £982, and a small drop in CAML:Central Asia Metals meant a £29 drop in potential profits, as they are now my only profitable share. The recent magic formula shares are only just in the red, so hoping a late rally next week will get them into profit.

Looks almost flat

As with the ISA, clinging to the trend line

The trading account looks like this after week 334 overall and week 22 of year 7.

			Weekly Change
Cash	£0.10		+£0
Portfolio cost	£1,849.21		+£0
Portfolio sell value (bid price - commission)	£590.95	(-68.0%)	-£18.52
Potential profits	£0		+£0
Year 7 Dividends	£0.00		+£0
Year 7 Interests	£0.01		+£0
Year 7 Profit	-£71.73		+£0
Yr 7 projected avg monthly profit	-£14.13	(-9.2%)	+£0.67
Dividends	£60.10		+£0
Interest	£0.01		+£0
Profit from sales	£154.87		+£0
Average monthly cash profit	£2.79	(1.8%)	-£0.01
(Sold stocks profit + Dividends - Fees / Months)

OPTI:Optibiotix continues to fall, so this account continues to be an unmitigated disaster.

I should maybe give up

We flirted above the trend line for quite a while, but it's determined to turn back downwards

It looks like there's going to be no news to save the PBX:Prebiotix Health share price when the lock-in ends, so I could easily see another £10k wiped off my portfolio at the start of the new year. It looks bad now, but it's going to get worse before it gets better. I'm also going to have no cash available when the JLP:Jubilee Metals warrant holder stops selling in January, so that will no doubt take off and I'll miss it.

It's getting harder and harder to summon up the enthusiasm to write this every week. It's just deepening my misery having to write about it. I'm hoping next week won't be another new low, so at least there will be something positive to write about at Christmas proper.